粗隆下截骨全髋关节置换术治疗Crowe IV型发育性髋关节发育不良的长期结局
该回顾性研究纳入1992至2005年间因Crowe IV型发育性髋关节发育不良接受非骨水泥全髋关节置换联合粗隆下截骨术的28髋(24例),平均随访18年。20年免于任何翻修生存率为79%,末次随访时未翻修髋均影像学固定良好,平均Harris髋关节评分81分。作者结论认为该术式长期随访假体生存良好、固定持久且临床结局可靠。
要点
- 20年免于任何翻修生存率为79%,5例翻修均发生在术后6年内,6年后无新翻修或再手术。
- 末次随访时所有未翻修髋影像学固定良好,平均Harris髋关节评分81分(平均随访15年时)。
- 作者结论认为非骨水泥全髋关节置换联合粗隆下截骨术治疗Crowe IV型发育性髋关节发育不良长期假体生存良好、固定持久、临床结局可靠。
核心结论
- 作者结论认为,非骨水泥全髋关节置换联合粗隆下截骨术治疗Crowe IV型发育性髋关节发育不良在长期(平均18年)随访中提供良好的假体生存、持久的固定和可靠的临床结局。
- 作者指出,在本系列中股骨假体无菌性松动罕见。
研究设计与样本
- 回顾性研究,经本机构全关节登记系统纳入1992年至2005年间因Crowe IV型发育性髋关节发育不良接受非骨水泥全髋关节置换联合粗隆下截骨术的28髋(24例)。
- 全髋关节置换时平均年龄48岁,女性占83%,平均体重指数27。
- 自原研究以来,5例患者死亡(包括1例双侧全髋关节置换者),5髋接受翻修,2例退出研究,1例失访;最终14髋获得随访,平均随访18年(范围12至28年)。
- 计算Kaplan-Meier生存曲线,复习X线片,并通过Harris髋关节评分评估临床结局。
主要发现
- 20年免于任何翻修生存率为79%。
- 共5例翻修:2例因股骨柄无菌性松动分别于10个月和2年行翻修,1例因股骨柄骨折于2年行翻修,1例因髋臼假体无菌性松动于1年行翻修,1例因聚乙烯内衬分离于6年行翻修。
- 术后6年后无新翻修或再手术。
- 末次随访时所有未翻修髋影像学固定良好。
- 平均随访15年时平均Harris髋关节评分为81分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 自原研究以来5例患者死亡、5髋接受翻修、2例退出研究、1例失访,最终仅14髋获得随访。
- 证据等级为治疗性IV级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cementless total hip arthroplasty (THA) with subtrochanteric shortening osteotomy (SSO) is a well-established treatment for Crowe IV developmental dysplasia of the hip (DDH). However, series to date are limited by mid-term follow-up. The purpose of this study was to evaluate the long-term (mean 18 years) implant survivorship, radiographic results, and clinical outcomes of our previously published series. METHODS: We retrospectively reviewed 28 hips (24 patients) that underwent cementless THA with SSO for Crowe IV DDH between 1992 and 2005 using our institutional total joint registry. The mean age at the time of THA was 48 years, 83% were women, and the mean body mass index was 27. Since the original study, five patients died, including a patient who had bilateral THAs; five hips were revised; two withdrew from the study; and one was lost to follow-up. As such, 14 hips were available for follow-up at a mean of 18 years (range, 12 to 28). Kaplan-Meier survivorship curves were calculated, radiographs were reviewed, and clinical outcomes were evaluated via the Harris Hip Score. RESULTS: The 20-year survivorship free of any revision was 79%. There were five revisions, including two for aseptic loosening of the femoral stem at 10 months and 2 years, one for stem fracture at 2 years, one for aseptic loosening of the acetabular component at one year, and one for polyethylene liner dissociation at 6 years. There were no new revisions or reoperations after 6 years. All unrevised hips were radiographically well-fixed at the most recent follow-up. The mean Harris Hip Score was 81 at a mean of 15 years. CONCLUSIONS: Cementless THA with SSO for Crowe IV DDH provides good implant survivorship with durable fixation and reliable clinical outcomes at long-term (mean 18 years) follow-up. In this series, femoral aseptic loosening was rare. LEVEL OF EVIDENCE: Therapeutic Level IV.
引用
- DeNovio AC, Bedard NA, Trousdale RT, et al. Long-Term Outcomes of Total Hip Arthroplasty With Subtrochanteric Osteotomy for Crowe IV Dysplasia. J Arthroplasty. 2025. PMID: 40345264. doi:10.1016/j.arth.2025.04.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。